{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T03:36:47Z","timestamp":1773113807839,"version":"3.50.1"},"reference-count":12,"publisher":"S. Karger AG","issue":"1-2","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"published-print":{"date-parts":[[2007]]},"abstract":"<jats:p>&lt;i&gt;Background:&lt;\/i&gt; Phase II\/III trials have shown that capecitabine is an active, well-tolerated therapy for metastatic breast cancer (MBC). We report clinical findings from an expanded access program enabling patients ineligible for investigative trials to receive capecitabine before its approval and availability. &lt;i&gt;Methods:&lt;\/i&gt; Patients pretreated with at least two chemotherapy regimens, including a taxane, for MBC received oral capecitabine until disease progression or unacceptable toxicity. &lt;i&gt;Results:&lt;\/i&gt; Six hundred and thirty-one patients received capecitabine (mean duration 3.8 months, range 0.1\u201324.7 months). The most common treatment-related grade 3\/4 toxicities were diarrhea (9%) and hand-foot syndrome (8%). Grade 3\/4 alopecia was absent and grade 3\/4 myelosuppression was rare. Dose was modified in 172 patients (27%). Objective response rate in 349 evaluable patients was 35%. Median time to progression (n = 604) was 6.6 months (95% confidence interval, CI, 5.6\u20137.6) and median overall survival (n = 569) was 10.0 months (95% CI, 8.5\u201315.3). &lt;i&gt;Conclusions:&lt;\/i&gt; Our findings in a cohort of patients with pretreated progressive breast cancer confirm the high efficacy and tolerability of outpatient capecitabine.<\/jats:p>","DOI":"10.1159\/000111094","type":"journal-article","created":{"date-parts":[[2007,11,14]],"date-time":"2007-11-14T10:29:10Z","timestamp":1195036150000},"page":"51-57","source":"Crossref","is-referenced-by-count":19,"title":["An Open-Label, Multicenter Study of Outpatient Capecitabine Monotherapy in 631 Patients with Pretreated Advanced Breast Cancer"],"prefix":"10.1159","volume":"72","author":[{"given":"M.","family":"Venturini","sequence":"first","affiliation":[]},{"given":"R.","family":"Paridaens","sequence":"additional","affiliation":[]},{"given":"D.","family":"Rossner","sequence":"additional","affiliation":[]},{"given":"M.M.","family":"Vaslamatzis","sequence":"additional","affiliation":[]},{"given":"J.W.R.","family":"Nortier","sequence":"additional","affiliation":[]},{"given":"M.","family":"Salzberg","sequence":"additional","affiliation":[]},{"given":"H.","family":"Rodrigues","sequence":"additional","affiliation":[]},{"given":"R.","family":"Bell","sequence":"additional","affiliation":[]}],"member":"127","published-online":{"date-parts":[[2007,11,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016%2FS0959-8049%2898%2900058-6"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007%2Fs002800050043"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002%2F1097-0142%2820011001%2992%3A7%3C1759%3A%3AAID-CNCR1691%3E3.0.CO%3B2-A"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.ejca.2003.11.007"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093%2Fannonc%2Fmdg346"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2005.05.098"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038%2Fsj.bjc.6600261"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1023%2FA%3A1012281104865"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2005.02.167"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2002.09.002"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016%2FS0959-8049%2802%2900238-1"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007%2Fs10549-004-1282-3"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/111094","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/111094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T02:12:20Z","timestamp":1745460740000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000111094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007]]},"references-count":12,"journal-issue":{"issue":"1-2","published-online":{"date-parts":[[2007,11,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000111094","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"value":"0030-2414","type":"print"},{"value":"1423-0232","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007]]}}}